 NEW YORK, Nov. 09, 2020 GLOBE NEWSWIRE -- Checkpoint Therapeutics, Inc. Checkpoint NASDAQ: CKPT, a clinical-stage immunotherapy and targeted oncology company, today announced updated interim results from the ongoing global, open-label, multicohort Phase 1 clinical trial of its anti-PD-L1 antibody, cosibelimab, in patients with advanced cancers, including a cohort of patients with previously untreated high PD-L1 expressing advanced non-small cell lung cancer NSCLC. The updated interim results are being presented in a poster presentation at the Society for Immunotherapy of Cancer SITC 35th Anniversary Annual Meeting being held virtually from November 9-14, 2020. 